MYC in cancer: from undruggable target to clinical trials Nature Reviews Drug Discovery - Oncogene MYC has been considered ‘undruggable’ for many decades. This Review provides an overview of the various strategies to inhibit MYC, focusing on...

We are delighted to share that the review “MYC in cancer: from undruggable target to clinical trials” by Jonathan Whitfield and @lsoucek.bsky.social is finally out in Nature Review Drug Discovery. What an amazing journey this has been and still promises to be!
rdcu.be/eawOK

@lsoucek.bsky.social is presenting today a seminar at UB regarding the challenge associated to the development of a MYC inhibitor. Info below.